American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
Primary Prevention of Heart Attacks: The Clinical and Economic Benefits of Epi+Gen CHD
- Primary Prevention of Heart Attacks: The Clinical and Economic Benefits of Epi+Gen CHD
Every year, about 805,000 people in the United States have a heart attack, with someone experiencing a heart attack every 40 seconds. - Heart disease is the leading cause of death for both men and women.
- In peer-reviewed studies, Epi+Gen CHD was more cost-effective and more sensitive for assessing heart attack risk compared to standard lipid-based risk calculators.
- Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks.